CONSORT-DEFINE Explanation and Elaboration: Recommendations for Enhancing Reporting Quality and Impact of Early Phase Dose-finding Clinical Trials

Funding: This work is a further extension of the CONSORT-DEFINE study, which was funded by the UK Medical Research Council (MRC)-National Institute for Health and Care Research (NIHR) Methodology Research Programme (MR/T044934/1). The Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU) receives programmatic infrastructure funding from Cancer Research UK (C1491/A25351; CTUQQR-Dec 22/100 004), which has contributed to accelerating the advancement and successful completion of this work.

References

Harrington J, Wheeler G, Sweeting M, Mander A, Jodrell D . Adaptive designs for dual-agent phase I dose-escalation studies. Nat Rev Clin Oncol. 2013; 10(5):277-88. DOI: 10.1038/nrclinonc.2013.35. View

Slingluff Jr C, Petroni G, Chianese-Bullock K, Wages N, Olson W, Smith K . Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63). J Immunother Cancer. 2021; 9(1). PMC: 7825263. DOI: 10.1136/jitc-2020-000934. View

Hopewell S, Hirst A, Collins G, Mallett S, Yu L, Altman D . Reporting of participant flow diagrams in published reports of randomized trials. Trials. 2011; 12:253. PMC: 3260171. DOI: 10.1186/1745-6215-12-253. View

Dite W, Langford Z, Cumming T, Churilov L, Blennerhassett J, Bernhardt J . A Phase 1 exercise dose escalation study for stroke survivors with impaired walking. Int J Stroke. 2015; 10(7):1051-6. DOI: 10.1111/ijs.12548. View

Orkin A, Gill P, Ghersi D, Campbell L, Sugarman J, Emsley R . Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. JAMA. 2021; 326(3):257-265. DOI: 10.1001/jama.2021.9941. View

Smit M, Sander A, Ariaans M, Fougeroux C, Heinzel C, Fendel R . First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2. Lancet Microbe. 2023; 4(3):e140-e148. PMC: 9848408. DOI: 10.1016/S2666-5247(22)00337-8. View

Kato T, Kudo T, Kagawa Y, Murata K, Ota H, Noura S . Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer. Sci Rep. 2023; 13(1):2331. PMC: 9911606. DOI: 10.1038/s41598-022-24057-0. View

Butcher N, Monsour A, Mew E, Chan A, Moher D, Mayo-Wilson E . Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022; 328(22):2252-2264. DOI: 10.1001/jama.2022.21022. View

Iasonos A, OQuigley J . Sequential monitoring of Phase I dose expansion cohorts. Stat Med. 2016; 36(2):204-214. PMC: 4976081. DOI: 10.1002/sim.6894. View

10.

Wrangle J, Velcheti V, Patel M, Garrett-Mayer E, Hill E, Ravenel J . ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018; 19(5):694-704. PMC: 6089612. DOI: 10.1016/S1470-2045(18)30148-7. View

11.

Lee V, Wang J, Zahurak M, Gootjes E, Verheul H, Parkinson R . A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan. Clin Cancer Res. 2018; 24(24):6160-6167. DOI: 10.1158/1078-0432.CCR-18-0421. View

12.

Grayling M, Mander A . Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported Adequately. JCO Precis Oncol. 2021; 5. PMC: 8691516. DOI: 10.1200/PO.21.00276. View

13.

Pearson A, Federico S, Aerts I, Hargrave D, Dubois S, Iannone R . A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors. Oncotarget. 2016; 7(51):84736-84747. PMC: 5356695. DOI: 10.18632/oncotarget.12450. View

14.

Shepshelovich D, Goldvaser H, Wang L, Razak A . Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database. Invest New Drugs. 2017; 36(5):933-938. DOI: 10.1007/s10637-017-0549-6. View

15.

Koyama T, Shimizu T, Iwasa S, Fujiwara Y, Kondo S, Kitano S . First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. Cancer Sci. 2019; 111(2):571-579. PMC: 7004556. DOI: 10.1111/cas.14265. View

16.

Zhang P, Xu B, Gui L, Wang W, Xiu M, Zhang X . A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer. Biomark Res. 2021; 9(1):24. PMC: 8042970. DOI: 10.1186/s40364-021-00271-2. View

17.

Exley A, Rantell K, McBlane J . Clinical development of cell therapies for cancer: The regulators' perspective. Eur J Cancer. 2020; 138:41-53. DOI: 10.1016/j.ejca.2020.07.006. View

18.

Iyer S, Beck J, Stewart A, Shah J, Kelly K, Isaacs R . A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol. 2014; 167(3):366-75. DOI: 10.1111/bjh.13056. View

19.

Li J, Tian Y, Zheng M, Ge J, Zhang J, Kong D . Anlotinib plus chemotherapy for T790M-negative EGFR-mutant non-sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial. Thorac Cancer. 2022; 13(24):3496-3503. PMC: 9750808. DOI: 10.1111/1759-7714.14713. View

20.

van Gerven J, Bonelli M . Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products. Br J Clin Pharmacol. 2018; 84(7):1401-1409. PMC: 6005602. DOI: 10.1111/bcp.13550. View